latam

Regístrate
Invertir conlleva riesgos y puede no ser adecuado para todos los inversores.

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Cytokinetics Inc
Search

Cytokinetics Inc

Cerrado

Sector Salud

55.83 3.22

Compra Fuerte

Precios actualizados 13 sept 2024, 19:59 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

55.11

Máximo

55.91

Métricas clave

By Trading Economics

Ingresos

-7.7M

-143M

Ventas

24M

25M

BPA

0.08

Margen de beneficio

-570.761

Empleados

423

EBITDA

-622K

-117M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+46.47 upside

Dividendos

By Dow Jones

Próximas Ganancias

31 oct 2024

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-58M

5.9B

Apertura anterior

52.61

Cierre anterior

55.83

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

97 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

54.22 / 56.275 Soporte y Resistencia

Cytokinetics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2024, 15:26 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

DJ

Leer

11 ene 2024, 17:47 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal

DJ

Leer

8 ene 2024, 18:28 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

DJ

Leer

5 jun 2024, 14:14 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

DJ

Leer

11 ene 2024, 17:47 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis Pursuit of Cytokinetics Cools -- Update

DJ

Leer

11 ene 2024, 17:19 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis Pursuit of Cytokinetics Cools -- WSJ

DJ

Leer

11 ene 2024, 17:19 UTC

Adquisiciones, fusiones, absorciones

Swiss Drug Maker Had Been Expected to Clinch Deal for Heart-Drug Developer as Soon as This Week -- WSJ

DJ

Leer

11 ene 2024, 17:19 UTC

Adquisiciones, fusiones, absorciones

Novartis Pursuit of Cytokinetics Cools, Sources Say -- WSJ

DJ

Leer

8 ene 2024, 21:42 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. -- IBD

DJ

Leer

8 ene 2024, 19:13 UTC

Adquisiciones, fusiones, absorciones

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal -- IBD

DJ

Leer

8 ene 2024, 18:25 UTC

Adquisiciones, fusiones, absorciones

Novartis, Cytokinetics Near Merger: Report -- MarketWatch

DJ

Leer

8 ene 2024, 18:14 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis in Advanced Talks to Buy Cytokinetics -- Update

DJ

Leer

8 ene 2024, 17:56 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Novartis in Advanced Talks to Buy Cytokinetics -- WSJ

DJ

Leer

8 ene 2024, 17:56 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Reached as Soon as This Week, Sources Say -- WSJ

DJ

Leer

8 ene 2024, 17:56 UTC

Adquisiciones, fusiones, absorciones

Novartis in Advanced Talks to Buy Cytokinetics, Sources Say -- WSJ

DJ

Leer

31 oct 2023, 17:49 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Cytokinetics May Have Some Tire Kickers -- Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

Cytokinetics Inc Esperado

Precio Objetivo

By TipRanks

46.47% repunte

Estimación a 12 meses

Media 81.85 USD  46.47%

Máximo 107 USD

Mínimo 60 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cytokinetics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

11

Comprar

3

Mantener

0

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Cytokinetics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

54.22 / 56.275Soporte y Resistencia

Corto Plazo

Bullish Evidence

Recent bullish events outweigh bearish events.

Medio plazo

Bearish Evidence

Recent bearish events outweigh bullish events.

Largo Plazo

Weak Bearish Evidence

Bearish events outweigh bullish events.

Sentimiento

By Acuity

97 / 365 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Cytokinetics Inc

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Otras acciones del sector

LLY

Eli Lilly and Co.

922.4

↓-0.08%

UNH

UnitedHealth Group Inc

589.22

↓-0.85%

NVO

Novo Nordisk A-S

137.37

↑ +0.29%

JNJ

Johnson and Johnson

166.55

↑ +0.63%

ABBV

AbbVie Inc

195.28

↑ +0.62%